Author: Charmaine Fraser

Unless otherwise defined herein, the capitalised terms used in this announcement have the same meaning as those used in the Company's announcements released on 13 February 2025.     Physiomics plc (AIM: PYC), is pleased to announce, further to the announcements made on 13 February 2025, the completion of the WRAP Retail Offer, at the same price as the previously announced Placing (together the “Fundraise”). The WRAP Retail...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE...

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the joint online publication in collaboration with Merck KGaA entitled ‘Semi-mechanistic efficacy model for PARP + ATR inhibitors – application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs’ in the British Journal of Cancer.   The...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is trading in line with market expectations for the full year ending 30 June 2025.   The Board expects that total income for the current financial year, driven by contracts already signed, will be in line with market...

TR-1: Standard form for notification of major holdings Please click here to read in full....

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the joint online publication with Astellas Pharma Inc. (“Astellas”) of an original peer reviewed article “A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination with Pembrolizumab” in the journal “CPT: Pharmacometrics & Systems...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is delighted to announce that the Innovate UK Funded project called PREDICT-ONC has now received both regulatory and ethical approval.   The Company’s personalised dosing software has been developed primarily with grant funding from UK bodies, including £68,000 from Innovate UK (March 2018), £150,000...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.   The project will involve the application of Pharmacokinetic-Pharmacodynamic (PK/PD) modelling to inform the Target Candidate Profile (“TCP”) of a key asset in Numab Therapeutic’ pipeline. Delivery of the project...